Best Immunotherapy & CAR-T Cell Therapy hospitals in New Delhi

CAR-T cell therapy is available in New Delhi for specific types of blood cancer. Treatment modifies a patient's own immune cells in a laboratory to fight cancer. Patients access this biological care through specialised oncology, or cancer care, departments in the city. Medical teams evaluate each case to confirm if cellular therapy is suitable.

CAR-T cell therapy is a treatment that alters T-cells, which are white blood cells, to attack cancer. Specialists extract T-cells from the blood and add a special receptor in a laboratory setting. These altered cells are grown and returned to the patient by intravenous, or vein, infusion. The reinfused cells target specific markers on cancer cells to destroy them.

CAR-T cell therapy treats certain types of leukaemia, lymphoma, and multiple myeloma. Leukaemia is a blood cancer, while lymphoma affects the lymphatic system, which fights infection. Doctors recommend this therapy mainly for cases where standard treatments have stopped working. Eligibility depends on the exact cancer subtype, previous treatments, and overall patient health.

Immunotherapy cost in New Delhi depends on the chosen medication, dosage, and therapy duration. Biological drugs and cellular therapies require precise laboratory preparation, which affects total expenses. Additional fees include inpatient stay, clinical monitoring, and diagnostic tests before treatment begins. Patients should request an itemised cost estimate from the hospital coordinator before travelling for care.

CAR-T cell therapy is necessary when blood cancer recurs or resists standard treatment options. Conventional chemotherapy, or cancer drug treatment, may no longer control the disease. Cellular therapy provides a targeted biological approach that trains the immune system against resistant cells. This option offers new therapeutic possibilities for patients with refractory, or non-responsive, cancers.

Cytokine release syndrome and immune system neurotoxicity require close clinical monitoring during CAR-T therapy. Cytokine release syndrome is a strong inflammatory response causing high fever and flu-like symptoms. Neurotoxicity, or nervous system effect, involves temporary confusion or speech difficulties after cell infusion. Intensive care specialists monitor patients closely to manage these reactions quickly with targeted medications.

The full CAR-T cell therapy process usually takes several weeks from cell collection to recovery. T-cells are harvested through apheresis, a process filtering white blood cells from blood. Genetic reprogramming in a specialised laboratory requires several weeks of preparation. After reinfusion, patients remain in or near the hospital for close monitoring over several weeks.

Patients undergo thorough health evaluations and low-dose conditioning chemotherapy before receiving CAR-T cells. Comprehensive blood tests, organ function checks, and imaging confirm fitness for treatment. Conditioning chemotherapy lowers existing immune cell counts to help the new modified cells multiply effectively. Medical teams guide patients through every preparation step before cell infusion.

Selecting an oncology centre requires checking laboratory capabilities, specialist experience, and emergency escalation protocols. Confirm that the hospital has dedicated cellular therapy units and trained intensive care staff. Review international quality accreditations to verify safety standards across all clinical departments. Discuss treatment protocols and support services with a coordinator before making your final selection.

Follow-up care after CAR-T cell therapy includes frequent blood testing, infection monitoring, and physical assessments. Patients must stay near the treatment centre for several weeks of initial monitoring after infusion. Long-term follow-up tracks immune system recovery and watches for delayed complications. Medical coordinators help international patients schedule remote consultations once they return home.